Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway

[1]  L. J. Lee,et al.  PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway , 2018, Cellular Physiology and Biochemistry.

[2]  Chi Wang,et al.  Downregulation of SREBP inhibits tumor growth and initiation by altering cellular metabolism in colon cancer , 2018, Cell Death & Disease.

[3]  Yan Fu,et al.  Lung fibroblasts promote metastatic colonization through upregulation of stearoyl-CoA desaturase 1 in tumor cells , 2018, Oncogene.

[4]  B. Shi,et al.  EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer , 2017, Molecular Cancer.

[5]  C. Taghibiglou,et al.  Sterol regulatory element-binding protein 1 inhibitors decrease pancreatic cancer cell viability and proliferation. , 2017, Biochemical and biophysical research communications.

[6]  B. Beutler,et al.  Skin-specific regulation of SREBP processing and lipid biosynthesis by glycerol kinase 5 , 2017, Proceedings of the National Academy of Sciences.

[7]  Dae-Ho Lee,et al.  Treatments for EGFR‐mutant non‐small cell lung cancer (NSCLC): The road to a success, paved with failures , 2017, Pharmacology & therapeutics.

[8]  R. Mancini,et al.  Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ , 2017, Oncogene.

[9]  Wei Huang,et al.  SREBP-1 is an independent prognostic marker and promotes invasion and migration in breast cancer , 2016, Oncology letters.

[10]  William Rom,et al.  Extracellular mRNA Detected by Tethered Lipoplex Nanoparticle Biochip for Lung Adenocarcinoma Detection. , 2016, American journal of respiratory and critical care medicine.

[11]  Liang Liu,et al.  SCD1 is associated with tumor promotion, late stage and poor survival in lung adenocarcinoma , 2016, Oncotarget.

[12]  David Gilligan,et al.  Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. , 2015, The Lancet. Oncology.

[13]  Lihua Huang,et al.  Mechanisms of resistance to EGFR tyrosine kinase inhibitors , 2015, Acta pharmaceutica Sinica. B.

[14]  M. Tsao,et al.  Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. , 2015, Translational lung cancer research.

[15]  Xiaojun Tan,et al.  A Kinase-Independent Role for EGF Receptor in Autophagy Initiation , 2015, Cell.

[16]  R. Mancini,et al.  Stearoyl-CoA desaturase-1 is a key factor for lung cancer-initiating cells , 2013, Cell Death and Disease.

[17]  J. Byrd,et al.  Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons. , 2013, Analytical chemistry.

[18]  P. Jänne,et al.  The quest to overcome resistance to EGFR-targeted therapies in cancer , 2013, Nature Medicine.

[19]  Claudio R. Santos,et al.  Lipid metabolism in cancer , 2012, The FEBS journal.

[20]  K. Dittmann,et al.  EGFR-mediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  I. Umelo,et al.  Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab , 2012, BMC Medicine.

[22]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[23]  L. Crinò,et al.  Advances on EGFR mutation for lung cancer. , 2012, Translational lung cancer research.

[24]  L. Chung,et al.  Activation of Androgen Receptor, Lipogenesis, and Oxidative Stress Converged by SREBP-1 Is Responsible for Regulating Growth and Progression of Prostate Cancer Cells , 2011, Molecular Cancer Research.

[25]  R. Coleman,et al.  The role of lipid droplets in metabolic disease in rodents and humans. , 2011, The Journal of clinical investigation.

[26]  A. Gemma,et al.  F1000 highlights , 2010 .

[27]  Kounosuke Watabe,et al.  Metabolic genes in cancer: their roles in tumor progression and clinical implications. , 2010, Biochimica et biophysica acta.

[28]  S. Horvath,et al.  EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy , 2009, Science Signaling.

[29]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[30]  J. Liao,et al.  Transcriptomic and network component analysis of glycerol kinase in skeletal muscle using a mouse model of glycerol kinase deficiency. , 2009, Molecular genetics and metabolism.

[31]  M. Hung,et al.  Survival of cancer cells is maintained by EGFR independent of its kinase activity. , 2008, Cancer cell.

[32]  S. Varambally,et al.  Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity , 2007, Oncogene.

[33]  Steve Horvath,et al.  Glycerol kinase deficiency alters expression of genes involved in lipid metabolism, carbohydrate metabolism, and insulin signaling , 2007, European Journal of Human Genetics.

[34]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[35]  Edward R B McCabe,et al.  Targeted disruption of glycerol kinase gene in mice: expression analysis in liver shows alterations in network partners related to glycerol kinase activity. , 2006, Human molecular genetics.

[36]  F. Foufelle,et al.  SREBP transcription factors: master regulators of lipid homeostasis. , 2004, Biochimie.

[37]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Manuel Hidalgo,et al.  Developing inhibitors of the epidermal growth factor receptor for cancer treatment. , 2003, Journal of the National Cancer Institute.

[39]  T. Jovin,et al.  Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. , 2003, Experimental cell research.

[40]  C. A. Guyer,et al.  Ligand- and kinase activity-independent cell survival mediated by the epidermal growth factor receptor expressed in 32D cells. , 2003, Experimental cell research.

[41]  J. Horton.  Sterol Regulatory Element-Binding Proteins (SREBPs) , 2002 .

[42]  J. Horton.  Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. , 2001, Biochemical Society transactions.

[43]  J. Dallongeville,et al.  Glycerol kinase deficiency: Evidence for complexity in a single gene disorder , 2001, Human Genetics.

[44]  A. Beaudet,et al.  X-linked glycerol kinase deficiency in the mouse leads to growth retardation, altered fat metabolism, autonomous glucocorticoid secretion and neonatal death. , 1997, Human molecular genetics.

[45]  R. G. Lamb,et al.  Effects of chronic insulin and glucagon exposure on the biosynthesis of glycerolipids by cultured hepatocytes. , 1982, The Journal of biological chemistry.

[46]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[47]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.